Funded Startups in Oss
Across the 5 most recent funded startups listed for Oss, the only clearly disclosed round above the low millions is Citryll’s $90M Series B on 2024-12-09;…
Across the 5 most recent funded startups listed for Oss, the only clearly disclosed round above the low millions is Citryll’s $90M Series B on 2024-12-09; it dwarfs the next-largest disclosed amount, RiboPro’s $2M on 2024-01-10, and far exceeds Orexa’s $520K on 2023-01-10. Four of the five entries are explicitly Biotechnology, creating a tight sector cluster even as stages vary.
The funding dates also cluster: 3 of the 5 rounds fall within 2022–2024 (Orexa 2023-01-10, RiboPro 2024-01-10, Citryll 2024-12-09). Two entries are temporally separated at the edges, with the most recent appearing in 2025 (Cantoni Therapeutics, Seed on 2025-09-15, undisclosed) and the oldest in 2022 (BioConnection on 2022-04-22, Secondary Market, undisclosed). Two of five disclosed amounts are undisclosed, further concentrating comparability in the three disclosed biotechnology rounds.
Most recent rounds
5 shownRelated listings
Frequently asked
Which disclosed rounds stand out in Oss, and how do they compare to the rest of the disclosed set?
Citryll’s $90M Series B on 2024-12-09 is an outlier in size versus the other disclosed amounts in the table: RiboPro’s $2M (2024-01-10) and Orexa’s $520K (2023-01-10). The remaining two most-recent entries (Cantoni Therapeutics on 2025-09-15 and BioConnection on 2022-04-22) list undisclosed amounts, so they don’t affect the disclosed ranking.
Do the funding dates cluster, or are rounds spread evenly over time?
They cluster around 2023–2024: Orexa (2023-01-10), RiboPro (2024-01-10), and Citryll (2024-12-09) account for 3 of the 5 rows. The rest sit at the temporal edges: BioConnection in 2022-04-22 and Cantoni Therapeutics in 2025-09-15.
Are any stages or classifications over-represented among the most recent entries?
Stage labels are mixed, but “Series Unknown” appears twice (RiboPro on 2024-01-10 and Orexa on 2023-01-10). “Undisclosed” amounts also appear twice (Cantoni Therapeutics, 2025-09-15 and BioConnection, 2022-04-22), limiting amount-based comparison to the remaining three rows with disclosed figures.
Is biotechnology over-represented in Oss relative to other sectors in this list?
Yes: 4 of the 5 companies are explicitly categorized under Biotechnology, covering Cantoni Therapeutics, Citryll, RiboPro, and Orexa, with BioConnection as the other Biotechnology entry (also Biotechnology-labeled). That makes biotechnology the dominant sector across both the 2022 and 2025 edge dates as well as the 2023–2024 cluster.
Which companies are most time-relevant based on recency within these 5 rows?
Within the most recent year window on the page, Cantoni Therapeutics (Seed, 2025-09-15, undisclosed) and Citryll (Series B, 2024-12-09, $90M) are the only entries dated in 2024–2025. The earlier set comprises RiboPro (2024-01-10, $2M), Orexa (2023-01-10, $520K), and BioConnection (2022-04-22, undisclosed).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.